Coverage
-
March 15, 2021
A federal judge in Massachusetts gave an initial nod to the proposed settlement of a trio of shareholder derivative suits against Acer Therapeutics Inc. that would see the company making a slate of corporate reforms to end allegations it misled investors about the prospects for a drug it was developing.
1 other articles on this case.
View all »